Teleflex Incorporated (TFX), a worldwide provider of medical devices has announced that its latest Arrow FlexTip Plus Closed Tip, Multi-Port epidural catheter is now available for sale in the U.S. The company received the 510(k) clearance for the catheter from U.S. Food and Drug Association (FDA) in May 2012.
Teleflex’s latest offering will enhance the company’s Arrow catheter portfolio and strengthen its Critical Care segment. The revenues for Critical Care segment edged up 0.2% year over year to $254.1 million in the second quarter of 2012 while total revenues came in at $383.3 million, up 0.6% year over year.
Management believes that performance in the most recent quarter validates the company’s focus to boost top-line and enhance its product portfolio.
The Arrow FlexTip Plus Closed Tip, Multi-Port epidural catheter is a development on the company’s market leading Arrow FlexTip Plus Open Tip, Single-Port epidural catheter. The Open Tip, Single-Port epidural catheter — the only coil-reinforced catheter — is well regarded in its ability to reduce complications which other epidural catheters have not been able to prevent, such as vein cannulations and paresthesia.
The statistical success of Open Tip, Single-Port catheter is supported by clinical data from over a decade. The new product uses the same technology as the Open Tip, Single Port catheter but its addition to the Arrow FlexTip Plus will render various drug dispersion choices in order to critically aid clinical results.
The FlexTip Plus Closed Tip, Multi-Port has a soft flexible tip with four lateral apertures to provide exceptional kink resistance and is based on proven technology.
The FlexTip Plus catheters are made of polyurethane unlike the majority of other spring wound nylon catheters. The polyurethane material provides symmetry between softness and strength for easier catheter insertion. It also reduces unnecessary catheter movement out of the epidural space, enhances block quality and patient outcomes.
The new addition to the Arrow catheter family will further support clinicians by reducing the problems faced by anesthesiologists on a regular basis. Management therefore rightly believes that the FlexTip Plus Closed Tip, Multi-Port can help anesthesiologists to improve the quality and standard of patient care.
Teleflex’s latest offering is now available in Arrow brand kits and also through Teleflex’s Arrow Select Kits program for inclusion in custom kits.
Teleflex, headquartered in Limerick, Pennsylvania, is a manufacturer and provider of medical devices used in critical care and surgery. Its move to divest OEM orthopedic along with the strategy of developing new, innovative products should help improve its financial performance in the long run. The company’s focus on profitable and consistent growth with new product introduction and portfolio expansion is yielding results.
However, Covidien (COV), C.R. Bard (BCR) and CareFusion (CFN) which operate in similar business segments, present a tough competitive landscape for Teleflex. Additionally, the company operates in a seasoned regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.
Teleflex currently retains a Zacks #4 Rank, which translates into a short-term Sell rating.
BARD C R INC (BCR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment